At the news
? NEUTRALIMPACT 2/10 3 filed Nov 12, 2026 at 16:01 ET
Three Form 3 filings were filed by new insiders (Laura Sandler, Michelle Pernice, Julianne Bruno) of Mentari Therapeutics, Inc. (formerly InMed Pharmaceuticals Inc.), each accompanied by a power of attorney. The filings disclose shares received in a merger that closed on November 6, 2026, where InMed Pharmaceuticals (the issuer) acquired Pre-Merger Mentari via a two-step merger. Pernice received 27,868 shares (19,740 restricted), Bruno received 33,442 shares (23,689 restricted), and Sandler's holdings are not stated. These are routine initial ownership filings following a reverse merger and do not convey new material information about the company's operations or financials.
- Three Form 3 filings were filed on November 12, 2026, for the period ending November 6, 2026.
- The filings relate to a merger effective November 6, 2026, where InMed Pharmaceuticals Inc. (issuer) acquired Pre-Merger Mentari Therapeutics via a two-step merger.
- Michelle Pernice received 27,868 shares of common stock (19,740 restricted, vesting through August 2029) in exchange for Pre-Merger Mentari shares at a ratio of 0.20065.
- Julianne Bruno received 33,442 shares of common stock (23,689 restricted, vesting through August 2029) in exchange for Pre-Merger Mentari shares at a ratio of 0.20065.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access